Statins and its Effects on Lipids and Glycemic Status: A Quasi-Experimental Study


  • Sikandar Hayat Khan Department of Pathology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Rahat Shahid Department of Radiology, Pakistan Navy Ship Hafeez, Hospital Islamabad Pakistan
  • Ayesha Hafeez Department of Pathology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Mehreen Gillani Department of Pathology, Pakistan Navy Ship Hafeez, Hospital Islamabad Pakistan
  • Zeeshan Ali Qureshi Department of Medicine, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Javeria Hafeez Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan



HMG CoA reductase inhibitors, Statin, Triglycerides, Glycemic Status


Objective: To measure changes in lipid and glucose parameters after initiating statin therapy.

Study Design: Quasi-experimental study.

Place and Duration of Study: Department of Pathology and Medicine, Naval Hospital, Islamabad Pakistan, from Nov 2018 to
Oct 2020.

Methodology: Thirty-nine male individuals participated in the study after a detailed explanation and consenting procedure.
At the outset of the study, baseline testing of fasting plasma glucose and lipid parameters was done. Participants were then
started with 10 mg of Atorvastatin/day for six weeks, with visits every two weeks for testing for lipids and glucose.

Results: The mean age of participants was 42.47+11.65 years. %Δ (change) in mean (X) from baseline to result of last reading at
six weeks for various evaluated parameters were as: %ΔX Fasting plasma glucose = +91.45, %ΔX total cholesterol=-139.63,
%ΔX fasting triglycerides=-1.04%ΔX LDLc= -150.49 and %ΔXHDLc= -105.25. For HDLC, 14/31 showed a rise in levels
compared to 17/31, who demonstrated a downward trend after starting statin therapy, indicating a differential response
among subjects taking statin therapy.

Conclusion: Mean glucose levels increased from baseline to six weeks, whereas the mean of all lipid indices (including HDLc)
declined in subjects on statin therapy.


Download data is not yet available.


Metrics Loading ...


Endo A. The discovery and development of HMG-CoA

reductase inhibitors. J Lipid Res 1992; 33(11): 1569-1582.

O'Keeffe AG, Nazareth I, Petersen I. Time trends in the

prescription of statins for the primary prevention of

cardiovascular disease in the United Kingdom: a cohort study

using The Health Improvement Network primary care data. Clin

Epidemiol 2016; 8: 123-132.

Cho KI, Sakuma I, Sohn IS, Hayashi T, Shimada K, Koh KK. Best

Treatment Strategies with Statins to Maximize the

Cardiometabolic Benefits. Circ J2018; 82(4): 937-943.

Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M, et al. Statin Use

and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26

Studies. Pancreas 2019; 48(2): 142-150.

McTaggart F, Jones P. Effects of statins on high-density

lipoproteins: a potential contribution to cardiovascular benefit.

Cardiovasc Drugs Ther 2008;22(4):321-338.

Puri R, Nissen SE, Shao M, Kataoka Y, Uno K, Kapadia SR, et al.

The beneficial effects of raising high-density lipoprotein

cholesterol depends upon achieved levels of low-density

lipoprotein cholesterol during statin therapy: Implications for

coronary atheroma progression and cardiovascular events. Eur J

Prev Cardiol 2016; 23(5): 474-485.

Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A,

Dunselman PH, Van der Bom JG, et al. Effect of rosuvastatin

versus atorvastatin treatment on paraoxonase-1 activity in men

with established cardiovascular disease and a low HDLcholesterol. Curr Med Res Opin 2007; 23(9): 2235-2240.

Catapano AL. Pitavastatin and HDL: Effects on plasma levels

and function(s). Atheroscler Suppl 2017; 27: e1-e9.

Adams SP, Sekhon SS, Tsang M, Wright JM. Fluvastatin for

lowering lipids. Cochrane Database Syst Rev 2018; 3(3):


Sonal Sekhar M, Unnikrishnan MK. South-Asian population has

a higher likelihood for diabetes risk for statins regardless of

potency. Med Hypotheses 2015; 84(3): 283-284.

Woo HI, Kim SR, Huh W, Ko JW, Lee SY. Association of genetic

variations with pharmacokinetics and lipid-lowering response to

atorvastatin in healthy Korean subjects. Drug Des Devel Ther

; 11: 1135-1146.

Wang P. Statin dose in Asians: is pharmacogenetics relevant?

Pharmacogenomics 2011; 12(11): 1605-1615.

Reiner Z. Managing the residual cardiovascular disease risk

associated with HDL-cholesterol and triglycerides in statintreated patients: a clinical update. Nutr Metab Cardiovasc Dis

; 23(9): 799-807.

Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert

E, et al. European Atherosclerosis Society Consensus Panel.

Adverse effects of statin therapy: perception vs. the evidence -

focus on glucose homeostasis, cognitive, renal and hepatic

function, haemorrhagic stroke and cataract. Eur Heart J 2018;

(27): 2526-2539.

Carmena R, Betteridge DJ. Diabetogenic Action of Statins:

Mechanisms. Curr Atheroscler Rep 2019; 21(6): 23.

Laakso M, Kuusisto J. Diabetes Secondary to Treatment with

Statins. Curr Diab Rep 2017; 17(2):1 0.

Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J,

Laakso M. Increased risk of diabetes with statin treatment is

associated with impaired insulin sensitivity and insulin

secretion: a 6 year follow-up study of the METSIM cohort.

Diabetologia 2015; 58(5): 1109-1117.

Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their

increased risk of inducing diabetes. Expert Opin Drug Saf 2015;

(12): 1835-1844.

Rochlani Y, Kattoor AJ, Pothineni NV, Palagiri RDR, Romeo F,

Mehta JL. Balancing Primary Prevention and Statin-Induced

Diabetes Mellitus Prevention. Am J Cardiol 2017; 120(7): 1122-

Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana

JS, et al. Triglyceride Levels and Residual Risk of Atherosclerotic

Cardiovascular Disease Events and Death in Adults Receiving

Statin Therapy for Primary or Secondary Prevention: Insights

From the KP REACH Study. J Am Heart Assoc 2021; 10(20):


Hirayama K, Ota T, Harada K, Shibata Y, Tatami Y, Harata S, et

al. Impact of Paradoxical Decrease in High-density Lipoprotein

Cholesterol Levels After Statin Therapy on Major Adverse

Cardiovascular Events in Patients with Stable Angina Pectoris.

Clin Ther 2017; 39(2): 279-287.




How to Cite

Sikandar Hayat Khan, Rahat Shahid, Hafeez A, Gillani M, Qureshi ZA, Hafeez J. Statins and its Effects on Lipids and Glycemic Status: A Quasi-Experimental Study. Pak Armed Forces Med J [Internet]. 2024 Apr. 29 [cited 2024 May 24];74(2):478-82. Available from:



Original Articles

Most read articles by the same author(s)